Previous studies have shown that in the HepG2 steatosis cell model, liver-targeted Gal-OSL/Res nanocarriers can effectively reduce liver lipid accumulation and reduce insulin resistance by regulating AMPK/SIRT/FAS/SREBP1c signaling pathway. This evidence concerns the gene GAL and steatosis.